U.S. Pharmacokinetics Services Market to Reach USD 0.97 Billion and Europe USD 0.80 Billion by 2035 as Biologics Bioanalysis, AI-Driven PK Modeling, and Model-Informed Drug Development Drive Growth.

Austin, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Pharmacokinetics Services Market size was valued at USD 1.38 Billion in 2025 and is expected to reach USD 3.02 Billion by 2035, growing at a CAGR of 7.70% from 2026 to 2035. Growth is expected to experience steady growth. Pharmacokinetics services include a detailed description of the movement of drugs in the body over time and include processes of absorption, distribution, metabolism and excretion which collectively determine dosing needs and safety of a potential drug.


Download the Pharmacokinetics Services Market Sample Report: https://www.snsinsider.com/sample-request/5723

Pharmacokinetics Services Market Key Highlights

  • Market size, 2025: USD 1.38 Billion
  • Market forecast, 2035: USD 3.02 Billion
  • CAGR: 7.70% from 2026 to 2035
  • Largest region: North America, approximately 37.1% share in 2025
  • Fastest-growing region: Asia Pacific
  • Largest drug type: Small Molecules, approximately 68% share in 2025
  • Fastest-growing drug type: Biologics & Large Molecules
  • Largest service type: Bioanalytical Services, approximately 42% share in 2025
  • Fastest-growing service type: PK/PD Modelling & Simulation
  • Largest clinical phase: Preclinical, approximately 35% share in 2025
  • Fastest-growing clinical phase: Phase I
  • Largest end user: Pharmaceutical & Biotechnology Companies, approximately 52% share in 2025
  • Fastest-growing end user: Contract Research Organizations

Market Relevance

Pharmacokinetics services have become central to drug development success, as every new IND application creates defined PK requirements from preclinical ADME work through clinical bioanalysis and PK/PD modeling. Regulatory frameworks such as the FDA's model-informed drug development guidance and ICH E11(R1) for pediatric extrapolation are turning PK modeling from an optional analysis into an expected part of regulatory submissions.

Pharmacokinetics Services Market Overview

The market spans bioanalytical services, PK/PD modeling and simulation, and related studies for small molecules and biologics across preclinical and clinical phases. Small molecules lead owing to established regulatory pathways, validated bioanalytical methods, and extensive historical PK data. Biologics and large molecules are expanding quickly as monoclonal antibodies, bispecifics, ADCs, gene therapies, and RNA therapeutics require more complex, multi-analyte PK study designs.

Strategic Market Outlook

Opportunities are arising from AI-powered PK prediction platforms that shorten modeling timelines while meeting regulatory standards, as shown by Labcorp's FDA-approved AI-based PK modeling software in 2024. Expansion of GLP- and GCP-accredited CROs in China, India, and Southeast Asia is also creating cost-competitive capacity that attracts outsourcing from international pharmaceutical clients.

High service costs and a shortage of specialized expertise remain the main challenges. Comprehensive PK programs often exceed the budgets of small biotechnology companies, forcing scope cuts or delays, while the limited pool of clinical pharmacologists and PK modelers with regulatory experience restricts how fast service providers can expand capacity.

Pharmacokinetics Services Market Regional Analysis

North America held the largest market share of around 37.1% in 2025, owing to a large skilled workforce, advanced bioanalytical infrastructure, and the presence of major pharmaceutical companies and CROs, with the U.S. accounting for about 85.9% and Canada about 12.6% of regional revenue.

The U.S. Pharmacokinetics Services Market was valued at USD 0.44 Billion in 2025 and is expected to reach USD 0.97 Billion by 2035, growing at a CAGR of 8.21% from 2026 to 2035, driven by strong clinical trial activity, FDA model-informed drug development guidance, and the presence of leading PK service providers.

Europe Pharmacokinetics Services Market was valued at USD 0.39 Billion in 2025 and is expected to reach USD 0.80 Billion by 2035, growing at a CAGR of 7.50% from 2026 to 2035. The European market growth is supported by EMA's regulatory framework, strong clinical trial activity, and leading CROs, with Germany accounting for around 22.3% of regional revenue, followed by the UK and Switzerland.

The Asia-Pacific region is projected to grow at the fastest rate during 2026-2035, due to China's expanding CRO industry, India's USD 265 million biotechnology research investment, Japan's adoption of model-informed drug development, and cost-competitive clinical trial infrastructure, with China contributing about 44.8% of regional revenue.

Buy the Pharmacokinetics Services Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/5723

Pharmacokinetics Services Market Segment Analysis

By Drug Type: Small Molecules held a market share of about 68% in 2025, owing to mature regulatory pathways and validated bioanalytical methods. Biologics & Large Molecules are the fastest-growing segment due to the pipeline shift toward antibodies, ADCs, and gene therapies.

By Service Type: Bioanalytical Services accounted for nearly 42% share in 2025, as accurate drug concentration measurement underpins all PK analysis. PK/PD Modelling & Simulation is growing the fastest, supported by regulatory acceptance of model-informed drug development.

By Clinical Phase: Preclinical captured a 35% share in 2025, since every program requires ADME characterization and toxicokinetic support before IND filing. Phase I is the fastest-growing phase, driven by intensive PK sampling in first-in-human studies.

By End User: Pharmaceutical & Biotechnology Companies made up the largest share of around 52% in 2025, backed by PK procurement across their clinical pipelines. Contract Research Organizations are growing the fastest as CROs outsource specialized modeling and large molecule bioanalysis.

Pharmacokinetics Services Market Key Trends

  • Wider use of PK/PD modeling and simulation supporting model-informed drug development
  • Rising biologics development increasing demand for immunogenicity and TMDD studies
  • AI and machine learning improving PK modeling efficiency and virtual population simulation
  • Growing adoption of PBPK modeling for better prediction of drug behavior
  • Expanding oncology pipelines driving demand for advanced PK services

Major key players include

  • Charles River Laboratories International Inc.
  • Covance Inc. (Labcorp Drug Development)
  • ICON plc
  • PAREXEL International Corporation
  • Certara L.P.
  • Eurofins Scientific
  • WuXi AppTec Co., Ltd.
  • Evotec AG
  • SGS SA
  • Frontage Laboratories
  • Pharmaceutical Product Development LLC (PPD)
  • MPI Research
  • GVK Biosciences
  • Envigo (Inotiv)
  • Pacific BioLabs
  • Absorption Systems (Cyprotex)
  • XenoTech by BioIVT
  • Aptuit (Evotec)
  • Creative Bioarray
  • Svar Life Science AB

Have questions or need custom research on the Pharmacokinetics Services Market? Schedule a call with our analyst team: https://www.snsinsider.com/enquiry/5723

CONTACT: About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com